{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-014153","form_type":"8-K","ticker":"ACET","cik":"0001720580","company_name":"Adicet Bio, Inc.","filed_at":"2025-02-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.581464+00:00","generated_at":"2026-05-27T02:46:57.811637+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Adicet Bio reports 3 patients each enrolled in Phase 1 trials of ADI-001 LN and ADI-270 ccRCC","bullets":["ADI-001 LN Phase 1: 3 patients enrolled as of Feb 2025; first dosed Nov 2024; ~12 sites activated; preliminary data due H1 2025.","ADI-001 additional autoimmune indications: Phase 1 enrollment to start Q1 2025 for SLE, systemic sclerosis, IIM, stiff person syndrome; preliminary data H2 2025.","ADI-270 ccRCC Phase 1: 3 patients enrolled; first dosed Dec 2024; ~7 sites activated; preliminary data expected H1 2025.","ANCA-associated vasculitis enrollment planned for H2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-014153","json":"https://secwatch.observer/filing/0000950170-25-014153.json","markdown":"https://secwatch.observer/filing/0000950170-25-014153.md","text":"https://secwatch.observer/filing/0000950170-25-014153.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720580/000095017025014153/0000950170-25-014153-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720580/000095017025014153/acet-20250205.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T02:46:57.811637+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}